These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26464261)

  • 41. Comparisons of Therapeutic Efficacy and Safety of Solifenacin versus Tolterodine in Patients with Overactive Bladder: A Meta-Analysis.
    Wang HT; Xia M
    Urol Int; 2019; 103(2):187-194. PubMed ID: 31170710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
    Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
    Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient Perception of Bladder Condition after Treatment with Solifenacin and Tolterodine in Overactive Bladder Patients.
    Pradhan T; Dhamala JN; Yadav SK; Deo A
    J Nepal Health Res Counc; 2023 Mar; 20(3):750-754. PubMed ID: 36974869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Young JG; Subramonian K
    JAMA; 2007 Mar; 297(11):1192-3; author reply 1193. PubMed ID: 17374809
    [No Abstract]   [Full Text] [Related]  

  • 45. [A role of fesoterodine in treatment of overactive bladder].
    Kupriyanov YA; Kasyan GR; Pushkar DY
    Urologiia; 2018 Dec; (6):155-162. PubMed ID: 30742396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
    Milsom I; Schiotz HA; Svensson M; Kilany S; Hansson F
    Scand J Urol; 2019 Aug; 53(4):246-254. PubMed ID: 31195868
    [No Abstract]   [Full Text] [Related]  

  • 47. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
    BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
    Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
    Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Krunal Vishavadia KV; Sandip Solanki SS; Hiren Prajapati HP; Madhu Sharma MS
    Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fesoterodine fumarate.
    Gomelsky A; Dmochowski RR
    Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
    Armstrong EP; Malone DC; Bui CN
    J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
    Milsom I; Axelsen S; Kulseng-Hansen S; Mattiasson A; Nilsson CG; Wickstrøm J
    Acta Obstet Gynecol Scand; 2009; 88(6):693-9. PubMed ID: 19384673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.